Copenhagen, Nov. 25, 2014 (GLOBE NEWSWIRE) -- Pursuant to section 29 of the Danish Securities Trading Act, ALK (ALKB:DC / OMX: ALK B / AKABY / AKBLF) has received notification from Invesco Limited, that Invesco Canada Ltd. has increased its ownership in ALK-Abello A/S.
Invesco Canada Ltd. now owns 7.81% of the company share capital equivalent to 719,047 B shares.
For further information please contact:
Jens Bager, President and CEO, tel. +45 4574 7576
Investor Relations: Per Plotnikof, tel. +45 4574 7527, mobile +45 2261 2525
Press: Martin Barlebo, tel. +45 4574 7901, mobile +45 2064 1143
ALK is a research-driven global pharmaceutical company focusing on allergy prevention, diagnosis and treatment. ALK is the world leader in allergy immunotherapy - a unique treatment of the underlying cause of allergy. The company has approximately 1,800 employees with subsidiaries, production facilities and distributors worldwide. ALK has entered into partnership agreements with Merck and Torii to commercialise sublingual allergy immunotherapy tablets in North America and Japan, respectively. The company is headquartered in Hoersholm, Denmark, and listed on NASDAQ Copenhagen. Find more information at www.alk.net.